Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Sofosbuvir/Ledipasvir for Hepatitis C Genotype 1-6 in Patients With Transfusion-Dependent Thalassemia: An Open Label Trial

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03032666
Recruitment Status : Completed
First Posted : January 26, 2017
Last Update Posted : October 11, 2018
Sponsor:
Collaborator:
Gilead Sciences
Information provided by (Responsible Party):
Ala'a Sharara, American University of Beirut Medical Center

Tracking Information
First Submitted Date  ICMJE January 24, 2017
First Posted Date  ICMJE January 26, 2017
Last Update Posted Date October 11, 2018
Actual Study Start Date  ICMJE May 1, 2017
Actual Primary Completion Date August 6, 2018   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: February 27, 2017)
Sustained Viral Response following 12-week therapy (SVR 12) with sofosbuvir/velpatasvir in transfusion-dependent patients with HCV genotype 1-6 [ Time Frame: 12 weeks ]
Via tests of HepC RNA levels
Original Primary Outcome Measures  ICMJE
 (submitted: January 25, 2017)
Sustained Viral Response following 12-week therapy (SVR 12) with sofosbuvir/velpatasvir in transfusion-dependent patients with HCV genotype 1-6 [ Time Frame: 12 weeks ]
Change History
Current Secondary Outcome Measures  ICMJE Not Provided
Original Secondary Outcome Measures  ICMJE Not Provided
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE Sofosbuvir/Ledipasvir for Hepatitis C Genotype 1-6 in Patients With Transfusion-Dependent Thalassemia: An Open Label Trial
Official Title  ICMJE Sofosbuvir/Ledipasvir for Hepatitis C Genotype 1-6 in Patients With Transfusion-Dependent Thalassemia: An Open Label Trial
Brief Summary

Sustained Viral Response following 12-week therapy (SVR 12) with sofosbuvir/ledipasvir in transfusion-dependent patients with HCV genotype 1-6

Secondary Objective(s):

Assessment of transfusion requirements Adverse events Efficacy in treatment-naïve vs. relapsers vs. null responders Efficacy in patients with advanced fibrosis/cirrhosis vs. F1, F2 by elastography

Detailed Description

Thalassemia is characterized by a defect in red blood cell production. The anemia is caused by destruction of the erythroblasts in the bone marrow, erythrocytes' hemolysis and disrupted erythropoiesis. The life-long need for transfusions makes patients vulnerable to transfusion transmitted viral infections especially hepatitis C virus (HCV). HCV infection is a widespread disease. It affects a large number of thalassemia patients and it is considered a major public health problem. Infection with HCV results in chronic infection in a huge proportion of infected individuals. Therefore, it has been suggested that early treatment of acute HCV may prevent the development of chronic hepatitis.

Several studies have dwelled on the efficacy of interferon therapy for acute HCV infection in adults. Newer pegylated interferons (PEG-IFN) were used in the treatment of adults with acute HCV which showed equally excellent results. However, in thalassemia patients, iron overload in the liver negatively affects the outcome of liver disease leading to more severe hepatic inflammation and fibrosis in chronic hepatitis C which decreases response to IFN therapy.

Ribavarin has also been added as a treatment option with IFN, but ribavirin in thalassemia patients increases transfusion need by a median of 30-40 %, but does not increase major adverse events or treatment withdrawal.

At the end of 2013, the Food and Drug Administration (FDA) approved a new direct-acting antiviral agent for the treatment of HCV infection: Sofosbuvir (Gilead Sciences). Ledipasvir (Gilead Sciences) is a new drug with potent activity against HCV genotypes 1a and 1b. The combination of ledipasvir and sofosbuvir resulted in high rates of response among patients with HCV genotype 1 infection who had received prior treatment with interferon-based regimens. Ledipasvir and sofosbuvir have been combined in a single fixed-dose tablet for use once daily (ledipasvir-sofosbuvir).

Using this drug for HCV therapy alone or in combination with IFN for 12 or 24 weeks, resulted in more than 90% response rates in patients from the general population.

Patients with transfusion-dependent thalassemia major are at increased risk of adverse events with pegylated interferon and ribavirin therapy for HCV due to a notable 30% increase in transfusion requirements during the 48-week therapy. Some patients are not eligible for other treatments as they relapsed or did not respond to previous Ribavarin and IFN regimens. Treatment naïve thalassemia patients with HCV will be exposed to anemia and transfusion-induced iron overload among other adverse events associated with Ribavarin and IFN. These patients in particular, in addition to treatment-naïve thalassemia patients, have limited alternative treatment options available and constitute an area of significant unmet clinical needs. There is currently no literature available showing the efficacy of sofosbuvir/ledipasvir in the treatment of thalassemia patients with hepatitis C. Therefore, this trial will study the efficacy of sofosbuvir/ledipasvir for hepatitis C genotype 1-6 in patients with transfusion-dependent thalassemia.

Ten patients from the Lebanese Chronic Care Center will be enrolled in this open label trial. Patients with transfusion dependent thalassemia with hepatitis C will be enrolled. Study patients will receive the treatment following informed consent and will be followed up regularly by the study coordinator for side effects, compliance and adherence. A blood test for hemoglobin and hematocrit and liver enzyme, will be done on all patients at baseline and then after 4 weeks, 8 weeks , and 12 weeks of therapy. At week 12, levels of the virus in the patient's blood will also be evaluated. Liver imaging will be done throughout the study.

Benefits of this study outweigh potential risks. Side effects of medications used are minor however potential benefits for the patients are possibly treating their hepatitis C with an approved drug (in the general population) at no cost, and for the society, the possibility of finding an oral treatment more efficient and tolerable in this special population.

As for privacy and confidentiality issues, all data will be under lock. The PI and the Co- Investigators will be the only ones with access to that data.

Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 4
Study Design  ICMJE Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE
  • Thalassemia
  • Hepatitis C
Intervention  ICMJE Drug: sofosbuvir/velpatasvir
treatment of hepatitis C genotype 1-6 in patients with transfusion-dependent thalassemia.
Other Name: Epclusa
Study Arms  ICMJE Experimental: sofosbuvir/velpatasvir
Epclusa
Intervention: Drug: sofosbuvir/velpatasvir
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Completed
Actual Enrollment  ICMJE
 (submitted: October 10, 2018)
7
Original Estimated Enrollment  ICMJE
 (submitted: January 25, 2017)
10
Actual Study Completion Date  ICMJE August 6, 2018
Actual Primary Completion Date August 6, 2018   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Transfusion Dependent thalassemia patients with HCV genotype 1-6
  • Age ≥18
  • Male and female
  • No evidence of hepatocellular carcinoma on ultrasound
  • No known drug allergy to the FDA approved drug to be used
  • Adequate iron chelation therapy
  • Compensated liver disease

Exclusion Criteria:

  • Age below 18
  • Chronic HCV genotypes 2 or 3
  • Allergy to study drug
  • Hepatocellular carcinoma
  • Inadequate iron chelation therapy
  • Decompensated liver disease
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 18 Years to 100 Years   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE Lebanon
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT03032666
Other Study ID Numbers  ICMJE IM.AS1.47
Has Data Monitoring Committee Yes
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: Yes
IPD Sharing Statement  ICMJE
Plan to Share IPD: No
Responsible Party Ala'a Sharara, American University of Beirut Medical Center
Study Sponsor  ICMJE Ala'a Sharara
Collaborators  ICMJE Gilead Sciences
Investigators  ICMJE Not Provided
PRS Account American University of Beirut Medical Center
Verification Date October 2018

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP